Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2020 Mar;43(3):289-304.
doi: 10.1007/s40618-019-01103-9. Epub 2019 Sep 5.

Sodium-glucose cotransporter 2 (SGLT-2) inhibitors and microvascular outcomes in patients with type 2 diabetes: systematic review and meta-analysis

E G Dorsey-Treviño #  1   2 , J G González-González #  1   2   3 , N Alvarez-Villalobos  2   3   4 , V González-Nava  2 , B M Contreras-Garza  2 , A Díaz González-Colmenero  1   2 , G Rodríguez-Tamez  2 , F J Barrera-Flores  1   2 , A M Farrell  5 , V M Montori  4   6 , R Rodriguez-Gutierrez  7   8   9   10
Affiliations
Meta-Analysis

Sodium-glucose cotransporter 2 (SGLT-2) inhibitors and microvascular outcomes in patients with type 2 diabetes: systematic review and meta-analysis

E G Dorsey-Treviño et al. J Endocrinol Invest. 2020 Mar.

Abstract

Purpose: The effect of the sodium-glucose 2 (SGLT-2) inhibitors on microvascular complications remains uncertain. We performed a systematic review to determine the efficacy of the SGLT-2 inhibitors on microvascular outcomes in patients with type 2 diabetes.

Methods: A comprehensive search was performed using Ovid, MEDLINE, EMBASE, Web of Science, and Scopus from inception to May 2019. Randomized trials comparing SGLT-2 inhibitors with placebo or other medication for type 2 diabetes for ≥ 4 weeks were included. Diabetes-related microvascular complications such as nephropathy, retinopathy, neuropathy, and peripheral vascular disease were evaluated. A random-effect model using mean differences for continuous outcomes and risk ratio for dichotomous outcomes was used to synthesize data. PROSPERO (CRD 42017076460).

Results: A total of 40 RCTs with overall moderate quality of evidence were included. SGLT-2 inhibitors reduced the risk of renal-replacement therapy (0.65; 95% CI 0.54-0.79), renal death (0.57; 95% CI 0.49-0.65), and progression of albuminuria (0.69; 95% CI 0.66-0.73). Conversely, they appeared ineffective in maintaining eGFR (0.33; 95% CI - 0.74 to 1.41) or reducing serum creatinine (- 0.07; 95% CI - 0.26 to 0.11), whereas urine albumin-creatinine ratio (- 23.4; 95% CI - 44.6 to - 2.2) was reduced. Risk of amputation was non-significant (1.30; 95% CI 0.93-1.83). No available data were found regarding neuropathy and retinopathy to perform a quantitative analysis.

Conclusion: SGLT-2 inhibitors may reduce the risk of renal patient-important outcomes but fail to improve surrogate outcomes. Apparently, no increased risk of amputations was observed with these medications. No data were available regarding other microvascular complications.

Keywords: Meta-analysis; Microvascular complications; Sodium-glucose cotransporter 2 inhibitors; Systematic review; Type 2 diabetes mellitus.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. McKinlay J, Marceau L (2000) US public health and the 21st century: diabetes mellitus. Lancet 356(9231):757–761 - PubMed - DOI - PMC
    1. Zimmet P (2003) The burden of type 2 diabetes: are we doing enough. Diabetes Metab 29(4 Pt 2):6s9-18 - PubMed - PMC
    1. Singleton JR, Smith AG, Russell JW, Feldman EL (2003) Microvascular complications of impaired glucose tolerance. Diabetes 52(12):2867–2873 - PubMed - DOI - PMC
    1. Fowler MJ (2008) Microvascular and macrovascular complications of diabetes. Clin Diabetes 26(2):77–82 - DOI
    1. King H, Aubert RE, Herman WH (1998) Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care 21(9):1414–1431 - PubMed - DOI - PMC

MeSH terms

Substances

LinkOut - more resources